title: Making sense of dual HER2-targeting in early breast cancer?
authors.affiliation: Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC (LAC); Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA (WB). lisa_carey@med.unc.edu.
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Carey
authors.affiliation: Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC (LAC); Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA (WB).
authors.forename: William
authors.initials: W
authors.lastname: Barry
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human